(Q34429882)

2 August 2017

title

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

6

Alexander Fosså

0 references

Frits van Rhee

1

object named as

Frits van Rhee

0 references

Seok-Goo Cho

13

0 references

author name string

Raymond S Wong

2

1 reference

2 August 2017

Nikhil Munshi

3

1 reference

2 August 2017

Jean-Francois Rossi

4

1 reference

2 August 2017

Xiao-Yan Ke

5

1 reference

2 August 2017

David Simpson

7

1 reference

2 August 2017

Marcelo Capra

8

1 reference

2 August 2017

Ting Liu

9

1 reference

2 August 2017

Ruey Kuen Hsieh

10

1 reference

2 August 2017

Yeow Tee Goh

11

1 reference

2 August 2017

Jun Zhu

12

1 reference

2 August 2017

Seok-Goo Cho

13

1 reference

2 August 2017

Hanyun Ren

14

1 reference

2 August 2017

James Cavet

15

1 reference

2 August 2017

Rajesh Bandekar

16

1 reference

2 August 2017

Margaret Rothman

17

1 reference

2 August 2017

Thomas A Puchalski

18

1 reference

2 August 2017

Manjula Reddy

19

1 reference

2 August 2017

Helgi van de Velde

20

1 reference

2 August 2017

Jessica Vermeulen

21

1 reference

2 August 2017

Corey Casper

22

1 reference

2 August 2017

publication date

17 July 2014

1 reference

Lancet Oncology Commission

2 August 2017

published in

1 reference

2 August 2017

volume

15

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

966-974

1 reference

Localized mediastinal lymphnode hyperplasia resembling thymoma

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Multicentric Giant Lymph Node Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Surgery in Castleman's disease: a systematic review of 404 published cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

The clinical spectrum of Castleman's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Castleman disease: an update on classification and the spectrum of associated lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

How I treat HIV-associated multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

Castleman's disease: systematic analysis of 416 patients from the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970319-5

7 January 2021

10.1016/S1470-2045(14)70319-5

Identifiers

DOI

1 reference

2 August 2017

1 reference